Provexis Signs Development Deal with DSM
By signing this deal, Provexis development pipeline is further strengthened and the opportunities available to commercialise the company's existing IP have been increased.
The company has a strong position in functional and medical foods for cardiovascular health, with its existing Fruitflow heart-health technology, together with work on cardiovascular inflammation being carried out in conjunction with the Institute of Food Research.
Stephen Moon, CEO of Provexis, said: â€œWe are delighted to announce that we have entered into the Agreement which further extends our strategic relationship with DSM. In recent months we have assessed the technology and believe that it will further strengthen our pipeline of cardiovascular-related technologies.
â€œThe collaborative approach facilitated by the Agreement will allow for the most effective commercialisation of the technology. In addition to this important new pipeline technology, the management team continues to assess further potential acquisitions.â€
In addition, the company has named Luke Heeney as new product director. Mr Heeney is responsible for the process of commercialising the company's IP from the development phase through to final product.
Mr Heeneyâ€™s main responsibilities will be to commercialise the blood glucose technology, but his role extends into other planned product developments.
Provexis discovers, develops and licenses scientifically - proven technologies for the global functional food, medical food and dietary supplement sectors.
Will the deal commercially benefit the firms?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.